Locally Advanced Head and Neck Squamous Cell Carcinoma

Oncology
4
Pipeline Programs
4
Companies
13
Clinical Trials
6 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 2 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
volrustomigPhase 35 trials
Active Trials
NCT07000149Active Not Recruiting1,116Est. Jul 2032
NCT06943833Active Not Recruiting30Est. Mar 2029
NCT06792695Recruiting120Est. Jun 2028
+2 more trials
LB
Lepu BiopharmaChina - Shanghai
1 program
1
PucotenlimabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT06959108Not Yet RecruitingEst. Oct 2029
M&
Merck & Co.RAHWAY, NJ
1 program
1
XevinapantPhase 23 trials
Active Trials
NCT06056310TerminatedEst. Aug 2024
NCT05724602Suspended230Est. Oct 2029
NCT05519540CompletedEst. Apr 2023
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
CemiplimabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT05376553Enrolling By Invitation24Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AstraZenecavolrustomig
AstraZenecavolrustomig
AstraZenecavolrustomig
Lepu BiopharmaPucotenlimab
AstraZenecavolrustomig
AstraZenecavolrustomig
Merck & Co.Xevinapant
AstraZenecavolrustomig
AstraZenecavolrustomig
AstraZenecavolrustomig
Merck & Co.Xevinapant
Merck & Co.Xevinapant
RegeneronCemiplimab

Clinical Trials (13)

Total enrollment: 4,039 patients across 13 trials

NCT07000149AstraZenecavolrustomig

A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

Start: Jul 2025Est. completion: Jul 20321,116 patients
Phase 3Active Not Recruiting
NCT06129864AstraZenecavolrustomig

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

Start: Dec 2023Est. completion: Sep 20301,145 patients
Phase 3Recruiting
NCT06097728AstraZenecavolrustomig

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Start: Nov 2023Est. completion: Nov 2028825 patients
Phase 3Recruiting
NCT06959108Lepu BiopharmaPucotenlimab

Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

Start: Oct 2025Est. completion: Oct 2029
Phase 2Not Yet Recruiting
NCT06943833AstraZenecavolrustomig

A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)

Start: Mar 2025Est. completion: Mar 202930 patients
Phase 2Active Not Recruiting
NCT06792695AstraZenecavolrustomig

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Start: Mar 2025Est. completion: Jun 2028120 patients
Phase 2Recruiting
NCT05724602Merck & Co.Xevinapant

Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Start: Nov 2023Est. completion: Oct 2029230 patients
Phase 2Suspended
NCT05775159AstraZenecavolrustomig

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Start: Apr 2023Est. completion: Oct 2027294 patients
Phase 2Recruiting
NCT05702229AstraZenecavolrustomig

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Start: Jan 2023Est. completion: Sep 2027240 patients
Phase 2Recruiting
NCT06366451AstraZenecavolrustomig

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Start: May 2024Est. completion: Apr 202515 patients
Phase 1Recruiting
NCT06056310Merck & Co.Xevinapant

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

Start: Jan 2024Est. completion: Aug 2024
Phase 1Terminated
NCT05519540Merck & Co.Xevinapant

PK Study of Xevinapant (Debio 1143) in Healthy East Asian Participants

Start: Sep 2022Est. completion: Apr 2023
Phase 1Completed
NCT05376553RegeneronCemiplimab

Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Start: Jul 2022Est. completion: Oct 202524 patients
Phase 1Enrolling By Invitation

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
3h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
3h ago

Office Administrator

SystImmune
3h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
6 actively recruiting trials targeting 4,039 patients
Monoclonal Antibody is the dominant modality (100% of programs)
4 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)